Ovarian Cancer

Patients with platinum-sensitive relapsed ovarian cancer given maintenance olaparib/cediranib had similar progression-free and overall survival rates vs those given olaparib alone.

In FRα-positive, platinum-resistant ovarian cancer, mirvetuximab soravtansine showed improvements in progression-free survival, overall response rate, and overall survival.

The combination of durvalumab, chemotherapy, and bevacizumab, followed by maintenance with olaparib, durvalumab, and bevacizumab, improved progression-free survival in newly diagnosed advanced ovarian cancer.

NXP800 was granted orphan drug designation from the FDA in ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers.

IMMN-001 significantly extended overall survival in patients with advanced ovarian cancer when combined with standard chemotherapy, according to phase 2 trial results.

Findings from the phase 2 NeoPembrOV study supported the addition of pembrolizumab to neoadjuvant chemotherapy before surgery in high-grade serous ovarian cancer.

The FDA has approved an individual patient investigational new drug application, allowing for a second dose of a novel CAR T-cell therapy for a patient with recurrent ovarian cancer.

A phase 2 trial demonstrated that nivolumab is effective and has a manageable safety profile in patients with mismatch repair deficiency uterine or ovarian cancers.

The FDA approved Tepylute, a ready-to-dilute formulation of an existing treatment for breast and ovarian adenocarcinoma.

A phase 1/2a study is investigating the novel antibody-drug conjugate for the treatment of ovarian and non–small cell lung cancers.

The FDA granted fast track status to lunresertib and camonsertib for platinum-resistant ovarian cancer with specific mutations, currently being evaluated for safety and efficacy in the phase 1 MYTHIC trial, with results expected in late 2024.

Topline findings from the phase 2 PICCOLO trial support the potential use of mirvetuximab soravtansine for the treatment of folate receptor alpha-positive, platinum-sensitive ovarian cancer.

Adding atezolizumab to bevacizumab plus chemotherapy did not derive benefit in recurrent ovarian cancer.

The addition of retroperitoneal lymphadenectomy to cytoreductive surgery did not improve survival in advanced ovarian cancer.

A rolling new drug application is being submitted to the FDA for an ovarian cancer treatment combination of avutometinib and defactinib.

For World Ovarian Cancer Day, Eirwen M. Miller, MD, discussed the current state of ovarian cancer treatment, new developments in the space, and unmet needs.

Sarah Lee, MD, MBA, discussed a study to better disaggregate the subgroup of Asian American patients with ovarian cancer.

ChatGPT was able to answer general questions about genetic counseling for gynecologic cancers, but some obstacles still remain.

A phase 2 trial plans to evaluate BAT8006 for the treatment of patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.

At a live virtual event, Michael McHale, MD, led a roundtable discussion on the use of PARP inhibition therapy for patients with advanced ovarian cancer.

Mirvetuximab soravatansine is now FDA-approved for the treatment of patients with folate receptor alpha-positive, platinum-resistant ovarian cancer

In heavily pretreated patients with recurrent low-grade serous ovarian cancer, the combination of avutometinib plus defactinib showing promising results within the phase 2 ENGOT-ov60/GOG-3052/RAMP 201 trial.

ctDNA offers clinicians the potential to determine whether to proceed with or discontinue PARP inhibitor maintenance therapy in patients with recurrent epithelial ovarian cancer.

Combining ixabepilone with bevacizumab generated improved survival rates and high response rates compared with ixabepilone monotherapy in platinum-resistant or platinum-refractory ovarian cancer.

Ex vivo generation of CD3-positive, CD56-positive Natural Killer-Like (NKT) with CRX100 was successful in all 7 patients with ovarian cancer in a phase 1 trial.